Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis.

J Drug Assess · 2015 · PMC4937628 · PMID 27536455

Europe PMC DOI

hedged sentences

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significancep = 0.12not close (p > 0.1)

There was no significant difference in ARR between RRMS and CIS patients (0.31 vs 0.25, p = 0.40) and, although there appeared to be a trend favoring longer interval to first relapse while taking IM IFNB in CIS patients, this result did not reach statistical significance (5.36 vs 6.16 years, p = 0.12).

also in 111,027 other papers

showed a trendno p-value reported

Duration of IM IFNB therapy also showed a trend to increase the odds of having a relapse while on therapy with a borderline p value of 0.05.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.